Myles Brown is Director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute and the Emil Frei III Professor of Medicine at Harvard Medical School. He obtained his undergraduate degree from Yale and his M.D. from Johns Hopkins. Following training in Internal Medicine at the Brigham and Women’s Hospital, a fellowship in Medical Oncology at the Dana-Farber and postdoctoral research at MIT, he joined the staff of the Dana-Farber and the faculty of Harvard Medical School. His research is focused on providing a detailed understanding of the factors underlying the hormone dependence of breast and prostate cancers with the goal of developing new therapies and improving outcomes for patients. He has been recognized for his work identifying the role of co-activators in steroid receptor action; elucidating the dynamic nature of co-regulator function; and defining steroid receptor cistromes. In 2010, together with Shirley Liu he founded the Center for Functional Cancer Epigenetics at the Dana-Farber with the goal of identifying epigenomic alterations in cancer including those that influence response to endocrine therapy. He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Sciences and the American Academy of Arts and Sciences.